Clover Biopharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	267.63	401.24	735.86	1,607	2,767
Short-Term Investments	3.77	-	2.94	2.94	61.09
Trading Asset Securities	14.62	14.78	14.17	13.93	30.91
Cash & Short-Term Investments	286.02	416.02	752.97	1,624	2,859
Cash Growth	-31.25%	-44.75%	-53.64%	-43.19%	263.55%
Accounts Receivable	0	40.99	24.11	-	-
Other Receivables	-	24.21	49.6	-	-
Receivables	0	65.21	73.71	-	-
Inventory	9.86	11.03	696.98	2,384	768.69
Restricted Cash	-	11.5	13.29	16.3	6.8
Other Current Assets	39.95	159.44	362.58	365.01	1,442
Total Current Assets	335.83	663.21	1,900	4,390	5,076
Property, Plant & Equipment	94.47	116.18	162.06	241.74	222.4
Other Intangible Assets	27.61	33.35	39.86	35	13.83
Other Long-Term Assets	-	-	-	28.04	32.93
Total Assets	457.92	812.74	2,101	4,695	5,346
Accounts Payable	107.99	120.45	247.83	856.96	588.56
Accrued Expenses	-	42.26	70.62	88.47	96.9
Short-Term Debt	-	73.97	308.06	294.06	-
Current Portion of Leases	10.61	12.18	18.54	23.57	21.48
Current Unearned Revenue	1,573	1,612	1,578	1,555	1,424
Other Current Liabilities	59.42	46.35	54.11	10.84	17.62
Total Current Liabilities	1,751	1,908	2,277	2,829	2,148
Long-Term Leases	-	3.5	7.85	36.74	46.44
Long-Term Unearned Revenue	3.4	25.3	44.36	2,497	1,932
Other Long-Term Liabilities	501.2	512.58	505.05	-	-
Total Liabilities	2,255	2,449	2,834	5,363	4,127
Common Stock	0.84	0.84	0.84	0.84	0.74
Additional Paid-In Capital	-	8,654	8,621	8,562	7,972
Retained Earnings	-	-10,544	-9,640	-9,502	-7,050
Treasury Stock	-0.02	-0.03	-0.03	-0.04	-0.05
Comprehensive Income & Other	-1,798	252.84	285.85	270.38	296.63
Shareholders' Equity	-1,797	-1,636	-732.83	-668.14	1,219
Total Liabilities & Equity	457.92	812.74	2,101	4,695	5,346
Total Debt	10.61	89.64	334.45	354.37	67.92
Net Cash (Debt)	275.41	326.38	418.52	1,270	2,791
Net Cash Growth	-15.62%	-22.02%	-67.04%	-54.51%	-
Net Cash Per Share	0.21	0.26	0.34	1.15	2.41
Filing Date Shares Outstanding	1,305	1,297	1,296	1,293	1,158
Total Common Shares Outstanding	1,305	1,297	1,296	1,293	1,158
Working Capital	-1,415	-1,244	-377.48	1,561	2,928
Book Value Per Share	-1.38	-1.26	-0.57	-0.52	1.05
Tangible Book Value	-1,825	-1,670	-772.69	-703.14	1,205
Tangible Book Value Per Share	-1.40	-1.29	-0.60	-0.54	1.04
Buildings	-	-	29.8	29.75	29.75
Machinery	-	-	147.25	128.37	101.65
Construction In Progress	-	-	25.28	44.08	32.15
Leasehold Improvements	-	-	35.79	31.6	11.38

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.